Loading
Life sciences · Journal article
Journal of Clinical Medicine · September 23, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Cholangiocarcinoma (CCA) remains an aggressive malignancy characterized by late-stage diagnosis, substantial molecular heterogeneity, and limited therapeutic options. Advances in molecular characterization have identified actionable alterations and expanded systemic treatment beyond conventional cytotoxic chemotherapy. This review examines three clinically relevant and mechanistically distinct targeted strategies in advanced CCA. Pemigatinib, a selective fibroblast growth factor receptor 1–3 (FGFR1–3) inhibitor, targets oncogenic signaling driven by FGFR2 fusions or rearrangements, which occur predominantly in intrahepatic CCA. Zanidatamab, a bispecific human epidermal growth factor receptor 2 (HER2)-directed antibody targeting two extracellular HER2 domains, provides a therapeutic approach for HER2-positive biliary tract cancers (BTCs). Ivosidenib, a selective inhibitor of mutant isocitrate dehydrogenase 1 (IDH1m), suppresses production of the oncometabolite D-2-hydroxyglutarate and targets the associated metabolic and epigenetic dysregulation in IDH1-mutant CCA. The review integrates the molecular rationale and pivotal clinical evidence supporting these therapies with their safety profiles, mechanisms of acquired resistance, biomarker selection, and therapeutic positioning. Particular attention is given to tumor heterogeneity and the tumor microenvironment as determinants of treatment response and resistance, as well as to emerging strategies involving next-generation inhibitors, antibody–drug conjugates, immunotherapy, rational combinations, and longitudinal molecular monitoring. Collectively, the clinical development of pemigatinib, zanidatamab, and ivosidenib demonstrates the therapeutic value of matching actionable molecular alterations with mechanism-based treatments, while highlighting the need to overcome resistance and optimize treatment sequencing to achieve more durable benefit in advanced CCA.